Cynata Therapeutics (ASX: CYP) is an Australian-listed company in the Healthcare sector with a market capitalisation of $4.4M and the 1697th-largest security on the ASX by market capitalisation. The CYP share price is $0.018, down 93.08% today and down 88.48% over the past 12 months. Shares have traded between $0.015 and $0.435 over the past 52 weeks. In its most recent reported period (ending 31 Dec 2025), Cynata Therapeutics reported revenue of $0 and a net loss of $2.7M.
About Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
